CFTX-1554 / Confo Therap, Eli Lilly - LARVOL DELTA

Safety and Tolerability of CFTX-1554 in Healthy Subjects (clinicaltrials.gov) - P1 | N=97 | Completed | Sponsor: Confo Therapeutics | Recruiting ➔ Completed

Trial completion

"$LLY just licensed in Confo Therapeutics' CFTX-1554 (inhibitor of angiotensin II type 2 receptor AT2R). $40m up front." (@JacobPlieth)

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554 (Businesswire) - "Confo Therapeutics...announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds....Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase 1. In addition, the agreement considers a program to further develop Confo’s existing therapeutic antibody candidates targeting the same receptor. Confo will receive a USD 40M upfront payment from Lilly as well as up to USD 590M in potential milestone payments per program and tiered royalties. Confo maintains a co-investment option to participate in the funding of future development programs after clinical proof-of-concept for additional royalties."

Licensing / partnership • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Confo Therapeutics Announces Poster Presentations on CFTX-1554 Preclinical Profiling and Mechanism of Action at the IASP 2022 World Congress on Pain (Businesswire) - "Confo Therapeutics...today announced that it will present highlights from the preclinical profiling of CFTX-1554, Confo’s lead clinical candidate in neuropathic pain, during the International Association for the Study of Pain (IASP) 2022 World Congress on Pain....Details and a brief summary of the two poster presentations are as follows: To investigate the anti-allodynic effects of CFTX-1554 in vivo, the molecule was tested in a CCI model....Additionally, data from rodent pharmacokinetic studies were collected to estimate target plasma concentrations for subsequent early-phase human clinical trials of the drug candidate....Rat in vivo dermal blood flow and ex vivo thoracic aorta studies were performed, with the aim to further understand the biology of AT2R and to evaluate the effect of AT2R modulators on, respectively, indirect capsaicin-induced and direct Ang II-induced vasodilation responses."

Preclinical • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain (Businesswire) - "Confo Therapeutics...today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554....The Phase 1 study will assess the safety, tolerability and pharmacokinetics of CFTX-1554 in healthy subjects....The randomized, double-blind, placebo-controlled first-in-human study will evaluate the safety, tolerability and systemic exposure (pharmacokinetics) of ascending single and multiple doses of CFTX-1554."

Trial status • CNS Disorders • Pain • Peripheral Neuropathic Pain

Safety and Tolerability of CFTX-1554 in Healthy Subjects (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Confo Therapeutics

New P1 trial

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform (Businesswire) - "Confo Therapeutics...today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational 'Steyaert patents'. The newly added patents...cover Confo’s well-established small molecule screening capabilities, which led to the discovery of CFTX-1554, Confo’s pre-clinical AT2R antagonist for the treatment of neuropathic pain..."

Patent • CNS Disorders • Pain • Peripheral Neuropathic Pain

Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain (Businesswire) - "Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, Confo’s lead candidate for neuropathic pain, which was initially discovered under a previous VLAIO research grant...'With the support of the VLAIO grant we are well-positioned to rapidly advance CFTX-1554 towards a first-in-human Phase I trial.'"

Financing • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain